Sandbox:AA

Aysha's sandbox

Management of ongoing Orthodromic AVRT

Class I
"1."(Level of Evidence: ) "
"2."(Level of Evidence: ) "

Class IIa
"1."(Level of Evidence: ) "

Class IIb
"1."(Level of Evidence:) "
"2."(Level of Evidence:) "

Common complications


Pathogen	Complications
Common complications
Group A Streptococcus	Suppurative complications Tonsillar abscess Sinusitis Otitis media Necrotizing fasciitis Meningitis Jugular vein thrombophlebitis Non suppurative complications Acute rheumatic fever (ARF) Scarlet fever Streptococcal toxic shock syndrome Acute glomerulonephritis Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS)
Influenza	Pneumonia Encephalitis Aseptic meningitis Guillain barre syndrome Transverse myelitis Myositis and rhabdomyolysis
Adenovirus	Laryngotracheitis Bronchitis Pneumonia Otitis media Meningoencephalitis Hepatitis Myocarditis Nephritis Neutropenia Disseminated intravascular coagulation
Cocksackie A virus	Aseptic meningitis Myocarditis Acute flaccid paralysis Conjunctival ulceration Brainstem encephalitis
Ebstein barr virus	Airway obstruction Splenic rupture X-linked lymphoproliferative disease Lymphomatoid granulomatosis
Less common complications
Gonococcus	Disseminated gonorrhea Meningitis Endocarditis
Diphtheria	Airway obstruction Myocarditis Polyneuropathies 10th cranial nerve disorder 9th cranial nerve disorder Peripheral motor neuropathy Diaphragm paralysis Neurogenic bladder dysfunction Acute renal failure Septicemia
Heamophilis influenza	Retropharyngeal abcess Epiglottitis
Fusobacterium necrophorum	Peritonsillar abscess Lemierre's syndrome
Parainfluenza virus	Retropharyngeal abcess Pneumonia


Pathogen	Complications
Diphtheria	A B C D
Gonococcus	A B C D
'	A B C D
Cocksackie A virus	A B C D
Ebstein barr virus	A B C D
Gonococcus	B C D
HIV	B C D

MRI syphilis 17628376

Among women the median prevalence of genital warts was 1.1% (range 0.8 to 2.3) across all jurisdictions, compared to 4.0% (range 2.9 to 4.7) for MSM and 4.9% (range 3.3 to 5.5) for MSW.


Varicella containing vaccines	Indications	Efficacy and immunogenicity	Recommended dose
Varicella vaccine (Varivax)	Approved for persons 12 months and older	Detectable antibody 97% of children 12 months through 12 years following 1 dose 99% of persons 13 years and older after 2 doses 70% to 90% effective against any varicella disease 90%-100% effective against severe varicella disease	2 doses separated by at least 4 weeks
Measles-mumps-rubella-varicella vaccine (ProQuad)	Approved for children 12 months through 12 years Do not use for persons 13 years and older	Efficacy of MMRV vaccine was inferred from that of MMR vaccine and varicella vaccine on the basis of noninferior immunogenicity Formal studies to evaluate the clinical efficacy of MMRV vaccine have not been performed^[1]	May be used for both first and second doses of MMR and varicella vaccines Minimum interval between doses is 3 months
Herpes zoster vaccine (Zostavax)	Approved for persons 50 years and older	Vaccine recipients 60 to 80 years of age had 51% fewer episodes of zoster Efficacy declines with increasing age Significantly reduces the risk of postherpetic neuralgia Reduces the risk of zoster 69.8% in persons 50 through 59 years of age	Single dose at age 60 years or older (whether or not they report a prior episode of herpes zoster)
New Herpes zoster vaccine (Shingrix)	Adults aged 50 years or older (first pivotal phase 3 trial) Adults aged 70 years and over (second pivotal phase 4 trial)	89% (95% confidence interval: 69– 97) efficacious in preventing PHN in people aged 70 years 91% (95% confidence interval: 76– 98) efficacious in people aged 50 years and over.	Two doses

20 mg/kg/dose twice daily (max = 500 mg/dose)